David E. I. Pyott - 15 Sep 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Director
Issuer ticker: TARS
Reported as of: 15 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Sep 2026, 16:47:49 UTC
Prior SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Sieckert, Attorney-in-Fact

Key filing fact

David E. I. Pyott filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 17 Sep 2026.

Key facts

This page summarizes David E. I. Pyott's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Sep 2026, 16:47.

Change

Previous filing in this sequence was filed on 29 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001051578 Primary reporting owner

PYOTT DAVID E I

Relationship: Director
Address: C/O TARSUS PHARMACEUTICALS, 17700 LAGUNA CANYON ROAD, FLOOR 4, IRVINE
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Signature date: 17 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARS transaction

Common Stock

Options Exercise

Transaction value
Shares: +201
Change %: +2.1%
Price
Shares after: 9,575
Date: 15 Sep 2026
Ownership: By the David E.I. Pyott Trust
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -201
Change %: -25%
Price: $0.000000^*
Shares after: 605
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 201
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F2

Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.

Footnote F3

Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F4

RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.